GlassScriptPhysician profile
Jacob Tangir
NPI 1245225762
$2,452.27
in general payments reported to CMS, 2019-2025
25 companies · $524 in 2025
The $524 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.51 · 2020: $122 · 2021: $259 · 2022: $745 · 2023: $443 · 2024: $261 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190 · Education: $19.81 · Gift: $19.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,189.89 |
| Education | $19.81 |
| Gift | $19.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $672.18 | 2022-2025 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $364.06 | 2020-2025 | Zejula, Jemperli |
| Abbvie INC. | $201.82 | 2019-2025 | Orilissa |
| Gynesonics, INC. | $136.71 | 2021 | |
| Astellas Pharma US INC | $135.21 | 2023-2025 | Veozah |
| Eisai INC. | $123.02 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $96.47 | 2019-2023 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $94.87 | 2022-2024 | Lynparza |
| Hologic Sales and Service, LLC | $81.29 | 2021-2024 | Acessa Provu System |
| Pfizer INC. | $71.77 | 2024-2025 | |
| Foundation Medicine, INC. | $64.52 | 2019-2020 | |
| Coopersurgical, INC. | $53.39 | 2023-2025 | Paragard T 380a, Ally II Ups, Paragard T 380a |
| Tempus Ai, INC | $47.04 | 2024 | |
| Myriad Genetic Laboratories, INC. | $41.65 | 2023 | Myrisk |
| Sumitomo Pharma America, INC. | $36.09 | 2023-2025 | Myfembree |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunogen, INC. | $35.83 | 2023 | Elahere |
| Clovis Oncology, INC. | $34.81 | 2020-2022 | |
| Biom'Up France Sas | $33.07 | 2021 | |
| Ethicon US, LLC | $26.50 | 2020 | |
| Olympus America INC. | $23.60 | 2023 | Olympus |
| Fennec Pharmaceuticals, INC. | $17.73 | 2025 | Fyarro |
| Tesaro, INC. | $16.71 | 2019 | |
| Exeltis, USA INC. | $15.93 | 2025 | Slynd |
| Axonics, INC. | $14.39 | 2023 | Axonics |
| Coherus Oncology, INC. | $13.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Tangir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.